Research
Hormonal
GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce major adverse cardiovascular events (MACE) and heart failure hospitalizations in patients with type 2 diabetes, independent of glycemic control.
If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about GLP-1 RAs or SGLT2is. These drugs protect your heart and kidneys, not just your blood sugar. They are often preferred over older medications like metformin if you have these risks.
StrongSupportsVERY_HIGH confidence
The development of GLP-1 RAs and SGLT2is has shifted T2D management by providing proven cardio-renal benefits in addition to glycemic control.
Why this rating
Supported by multiple large randomized controlled trials (LEADER, EMPA-REG, SOUL, SELECT).
Source
Pharmacologic Therapies for Type 2 Diabetes
Bryan Kuo et al. · NEJM Evidence · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →